Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serum amyloid A1 vaccine
- Development stage
- Preclinical
- Lead developer
- Southern Medical University
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Serum amyloid A1 vaccine is an investigational therapeutic vaccine designed to target serum amyloid A1 (SAA1), a kidney injury-associated molecule that plays a critical role in the development of renal fibrosis. SAA1 promotes chronic kidney disease (CKD) progression by damaging the peritubular capillary network, increasing vascular permeability, disrupting capillary integrity, and exacerbating renal ischemia and hypoxia via the CD36/JNK pathway. By inducing an immune response against SAA1, the vaccine aims to improve renal microcirculation, restore capillary density, and delay the progression of chronic kidney disease.
- Other names
- SAA1 vaccinationSAA-1 vaccinationSAA 1 vaccinationSAA1 vaccineSAA-1 vaccineSAA 1 vaccine
02
Targets
SAA1 (Serum amyloid A-2 protein)
Beyond the preview
Go deeper on serum amyloid A1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serum amyloid A1 vaccine.